Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Theranostics in immuno-oncology using nanobody derivatives.
Lecocq Q, De Vlaeminck Y, Hanssens H, D'Huyvetter M, Raes G, Goyvaerts C, Keyaerts M, Devoogdt N, Breckpot K. Lecocq Q, et al. Among authors: hanssens h. Theranostics. 2019 Oct 15;9(25):7772-7791. doi: 10.7150/thno.34941. eCollection 2019. Theranostics. 2019. PMID: 31695800 Free PMC article. Review.
Emerging applications of nanobodies in cancer therapy.
Awad RM, Meeus F, Ceuppens H, Ertveldt T, Hanssens H, Lecocq Q, Mateusiak L, Zeven K, Valenta H, De Groof TWM, De Vlaeminck Y, Krasniqi A, De Veirman K, Goyvaerts C, D'Huyvetter M, Hernot S, Devoogdt N, Breckpot K. Awad RM, et al. Among authors: hanssens h. Int Rev Cell Mol Biol. 2022;369:143-199. doi: 10.1016/bs.ircmb.2022.03.010. Epub 2022 May 18. Int Rev Cell Mol Biol. 2022. PMID: 35777863
Preclinical Targeted α- and β--Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies.
Puttemans J, Dekempeneer Y, Eersels JL, Hanssens H, Debie P, Keyaerts M, Windhorst AD, van der Aa F, Lecocq Q, Breckpot K, Morgenstern A, Bruchertseifer F, Lahoutte T, Devoogdt N, D'Huyvetter M. Puttemans J, et al. Among authors: hanssens h. Cancers (Basel). 2020 Apr 21;12(4):1017. doi: 10.3390/cancers12041017. Cancers (Basel). 2020. PMID: 32326199 Free PMC article.
The antigen-binding moiety in the driver's seat of CARs.
Hanssens H, Meeus F, De Veirman K, Breckpot K, Devoogdt N. Hanssens H, et al. Med Res Rev. 2022 Jan;42(1):306-342. doi: 10.1002/med.21818. Epub 2021 May 24. Med Res Rev. 2022. PMID: 34028069 Free PMC article. Review.
The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy.
Puttemans J, Stijlemans B, Keyaerts M, Vander Meeren S, Renmans W, Fostier K, Debie P, Hanssens H, Rodak M, Pruszynski M, De Veirman K, Vanderkerken K, Lahoutte T, Morgenstern A, Bruchertseifer F, Devoogdt N, D'Huyvetter M. Puttemans J, et al. Among authors: hanssens h. Mol Cancer Ther. 2022 Jan;21(1):159-169. doi: 10.1158/1535-7163.MCT-21-0220. Epub 2021 Oct 19. Mol Cancer Ther. 2022. PMID: 34667109 Free PMC article.
CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma.
De Veirman K, Puttemans J, Krasniqi A, Ertveldt T, Hanssens H, Romao E, Hose D, Goyvaert C, Vlummens P, Muyldermans S, Breckpot K, Bruchertseifer F, Morgenstern A, D'Huyvetter M, Devoogdt N. De Veirman K, et al. Among authors: hanssens h. Oncoimmunology. 2021 Nov 9;10(1):2000699. doi: 10.1080/2162402X.2021.2000699. eCollection 2021. Oncoimmunology. 2021. PMID: 34777918 Free PMC article.
Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization.
Hanssens H, Meeus F, De Vlaeminck Y, Lecocq Q, Puttemans J, Debie P, De Groof TWM, Goyvaerts C, De Veirman K, Breckpot K, Devoogdt N. Hanssens H, et al. Front Immunol. 2024 Apr 19;15:1389018. doi: 10.3389/fimmu.2024.1389018. eCollection 2024. Front Immunol. 2024. PMID: 38720898 Free PMC article.